Pulsed Electromagnetic Field Treatment With Dementia Patients

StatusRecruiting
PhaseNot applicable
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 12 months later Apr 30, 2026 → Apr 30, 2027
See other at-risk trials from Herrick Medical LLC

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary completion pushed from Apr 30, 2026 to Apr 30, 2027 Show 4 more changesShow less
    • Primary endpoints: details revised at 1 of 1 entry
    • Study completion pushed from Sep 30, 2026 to Sep 30, 2027
    • Eligibility criteria expanded, about 14 words
    • Secondary endpoints: details revised at 3 of 5 entries
  2. Eligibility criteria shortened, about 3 wordsv4
  3. Enrollment target: 40 to 48
    • Site contact updated
    • Study title shortened, about 1 word
    v3
  4. Trial status: Not Yet Recruiting to Recruitingv2 Show 5 more changesShow less
    • Primary endpoints: 4 to 1
    • Study sites: 2 to 1
    • Start date changed from estimate of Mar 15, 2025 to Apr 1, 2025
    • Eligibility criteria expanded, about 56 words
    • Secondary endpoints expanded, about 21 words
  5. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
An open label pilot study in mild to moderate AD/ADRD patients to assess the effects of treatment with ECHS AD/ADRD pulsed electromagnetic treatment device on disease progression. Enrolled patients will receive active devices. They will treat themselves at home three times a day for 15 minutes over 120 days. Primary end point is the The Alzheimer's Disease Assessment Scale-Cognitive Subscale. Participants will be followed-up for 9 months post-treatment.
Trial Details
NCT Number NCT06862557
Lead Sponsor Herrick Medical LLC
Collaborators: University of Miami
Conditions
(from sponsor)		 Alzheimer's Disease, Lewy Body Dementia, Vascular Dementia
Related terms Alzheimer Disease, Dementia, Vascular, Lewy Body Disease
Enrollment 48 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov